FDA Import Refusal AEK-7261265-6/13/1 — Boehringer Ingelheim Pharmaceuticals, Inc.
The FDA refused shipment AEK-7261265-6/13/1 from Boehringer Ingelheim Pharmaceuticals, Inc. (United States) on July 2, 2025. The refused product falls under Drugs and Biologics — EMPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- July 2, 2025
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCA73 EMPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75